NATIONWIDE AVAILABILITY THROUGH
PHIL, CAREPOINT, AND ASPN PHARMACIES

Trudhesa® (dihydroergotamine mesylate) nasal spray | Official Healthcare Professional (HCP) Site | Impel NeuroPharma®

Words "Years of DHE results don’t lie. Now they don’t lie in wait"
Words "Years of DHE results don’t lie. Now they don’t lie in wait"

Ready to deliver relief3,4


Logo for Precision Olfactory Delivery (POD®) Technology

Today, with Precision Olfactory Delivery (POD®) technology, patients can have the proven efficacy of dihydroergotamine mesylate (DHE) on demand for rapid, sustained, consistent relief, even when taken late into a migraine attack.2,4-7

Product image of Trudhesa® Precision Olfactory Delivery (POD®) vertical upright facing left on blue background

Exploratory endpoints and post hoc analyses of patient-reported efficacy data for some patients showed the following results7*:

Icon of Trudhesa® nasal spray

Rapid

Pain relief in as fast as 15 minutes6

Icon of Trudhesa® nasal spray

Sustained

Pain freedom lasted 2 days with 1 dose8

Icon of Trudhesa® nasal spray

Consistent

Delivered results time after time6

Icon of Trudhesa® nasal spray

No dosing window

Relief on their terms, even when taken late into a migraine attack5-7

Product image of Trudhesa® Precision Olfactory Delivery (POD®) vertical upright facing left on blue background

*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa®.7

Trudhesa Difference

Blue-tinted image of an actor portrayal of Trudhesa patient looking left down and smiling
Blue-tinted image of an actor portrayal of Trudhesa patient looking left down and smiling

References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Aurora S, Hocevar-Trnka J, Shrewsbury S. Acute treatment of migraine with INP104: exploratory efficacy from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Pharmaceuticals. 2020. 7. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients [published online ahead of print, 2021 Aug 7]. Headache. 2021;10.1111/head.14184. doi:10.1111/head.14184. 8. Tepper SJ, Ailani J, Shrewsbury SB, Aurora SK. Recurrence rates for INP104 for the acute treatment of migraine: results from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021.